ICU Medical, Inc. (NASDAQ:ICUI) Shares Bought by Deutsche Bank AG

Deutsche Bank AG increased its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 41.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,792 shares of the medical instruments supplier's stock after purchasing an additional 6,345 shares during the period. Deutsche Bank AG owned approximately 0.09% of ICU Medical worth $3,381,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Harvest Fund Management Co. Ltd purchased a new position in shares of ICU Medical in the fourth quarter worth approximately $33,000. Quarry LP grew its stake in shares of ICU Medical by 764.3% in the 4th quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 214 shares in the last quarter. Murphy & Mullick Capital Management Corp bought a new stake in shares of ICU Medical in the 4th quarter valued at approximately $52,000. Venturi Wealth Management LLC boosted its stake in shares of ICU Medical by 64.0% during the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier's stock worth $82,000 after purchasing an additional 206 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in ICU Medical by 88.8% during the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 300 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other ICU Medical news, COO Christian B. Voigtlander sold 4,959 shares of ICU Medical stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $130.03, for a total transaction of $644,818.77. Following the completion of the transaction, the chief operating officer now owns 4,307 shares in the company, valued at approximately $560,039.21. This trade represents a 53.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Elisha W. Finney sold 600 shares of the business's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $138.92, for a total value of $83,352.00. Following the completion of the transaction, the director now directly owns 3,252 shares of the company's stock, valued at $451,767.84. The trade was a 15.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,167 shares of company stock worth $3,571,788 in the last 90 days. Insiders own 1.50% of the company's stock.

ICU Medical Stock Down 1.3%

ICU Medical stock traded down $1.74 during midday trading on Friday, reaching $128.99. The company's stock had a trading volume of 149,163 shares, compared to its average volume of 277,478. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The stock has a market capitalization of $3.17 billion, a P/E ratio of -28.23 and a beta of 0.87. The stock's 50-day simple moving average is $139.66 and its 200-day simple moving average is $152.55. ICU Medical, Inc. has a 52-week low of $100.91 and a 52-week high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.49. The company had revenue of $599.49 million for the quarter, compared to the consensus estimate of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. ICU Medical's revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.96 EPS. On average, sell-side analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ICUI. Wall Street Zen upgraded ICU Medical from a "hold" rating to a "buy" rating in a report on Sunday, May 18th. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research report on Tuesday, April 8th. KeyCorp decreased their price objective on ICU Medical from $209.00 to $191.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Finally, Raymond James lowered their price objective on shares of ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, ICU Medical has a consensus rating of "Buy" and an average price target of $192.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.